Taken together with inhibition studies aiming the Akt/FOXM1 signaling, these results propose that transcription factor MYBL2 functions as a key downstream component of the Akt/FOXM1 axis, promoting the progression of gliomas [106]. The gene discussed is AKT1; the disease is central nervous system cancer.